Pulmonx (NASDAQ:LUNG – Get Free Report) and Sight Sciences (NASDAQ:SGHT – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.
Analyst Ratings
This is a summary of recent recommendations for Pulmonx and Sight Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulmonx | 1 | 0 | 3 | 0 | 2.50 |
| Sight Sciences | 1 | 2 | 5 | 0 | 2.50 |
Pulmonx presently has a consensus price target of $7.67, indicating a potential upside of 167.60%. Sight Sciences has a consensus price target of $10.31, indicating a potential downside of 4.51%. Given Pulmonx’s higher probable upside, equities analysts clearly believe Pulmonx is more favorable than Sight Sciences.
Risk and Volatility
Pulmonx has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.44, indicating that its stock price is 144% more volatile than the S&P 500.
Institutional & Insider Ownership
91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 55.5% of Sight Sciences shares are owned by institutional investors. 7.5% of Pulmonx shares are owned by insiders. Comparatively, 30.4% of Sight Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Pulmonx and Sight Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulmonx | -47.93% | -98.23% | -35.89% |
| Sight Sciences | -32.13% | -43.91% | -22.20% |
Valuation and Earnings
This table compares Pulmonx and Sight Sciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulmonx | $90.50 million | 1.38 | -$54.00 million | ($1.01) | -2.84 |
| Sight Sciences | $77.36 million | 7.76 | -$38.43 million | ($0.52) | -20.77 |
Sight Sciences has lower revenue, but higher earnings than Pulmonx. Sight Sciences is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.
Summary
Sight Sciences beats Pulmonx on 9 of the 13 factors compared between the two stocks.
About Pulmonx
Pulmonx is a medical technology company focused on minimally invasive treatments for people with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its products are used by clinicians to evaluate patients and provide bronchoscopic treatment. The company’s Zephyr Endobronchial Valve is a small, one-way valve placed in the lungs through a bronchoscope. By reducing airflow to targeted areas of a diseased lung, the treatment is intended to help lessen lung hyperinflation and improve the function of healthier areas.
About Sight Sciences
Sight Sciences is a medical technology company that develops and commercializes devices for ophthalmic care, with a focus on glaucoma and dry eye disease. Its products are designed to support minimally invasive procedures and address underlying causes of these conditions. The company’s portfolio includes the OMNI Surgical System, used in procedures to reduce eye pressure in patients with glaucoma, and TearCare, a device-based treatment for evaporative dry eye associated with meibomian gland dysfunction.
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.
